p 32

p32 inhibitor M36 is an inhibitor of p32 mitochondrial protein. It binds directly to p32 and inhibits the p32 association with LyP-1.

P32/98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.

C5aR2 agonist P32 (Ac-RHYPYWR-OH) is a selective agonist for C5aR2. It has demonstrated the ability to trigger various immunomodulatory activities both in vitro and in vivo, as it can downregulate C5aR1-mediated cellular signaling and can also operate in a C5aR1-independent manner.

C5aR2 agonist P32 acetate (Ac-RHYPYWR-OH), a selective agonist for C5aR2, has been shown to induce various immunomodulatory activities both in vitro and in vivo. It modulates cell signaling via the downregulation of C5aR1-mediated pathways and can also function independently of C5aR1.

DMP 323 is a potent inhibitor of HIV-1 protease.

BIBP 3226 trifluoroacetate is a mixed non-peptide neuropeptide Y Y1(NPY Y1) and neuropeptide FF (NPFF) receptor antagonist (Kivalues are 1.1, 79, 108, > 1000, > 1000 and >1000 for rNPY Y1, hNPFF2, rNPFF, rNPY Y2, rNPY Y4and rNPY Y5respectively). Produces an anxiogenic-like effect in rats following i.c.v. administration.

Tofimilast (CP-325366), a PDE4 inhibitor, is used potentially for the treatment of asthma and chronic obstructive pulmonary disease.

BIBP3226 TFA is an effective and selective antagonist of neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor (Kis: 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF).

Zaurategrast ethyl ester sulfate is a α4β1/α4β7 integrin antagonist, and used for the treatment of inflammatory and autoimmune disorders.

Zaurategrast ethyl ester is the ethyl ester prodrug of CT7758 and is an α4β1/α4β7 integrin antagonist. It is used for the treatment of inflammatory and autoimmune disorders.

Agerafenib hydrochloride, a highly potent inhibitor of BRAFV600E (Kd: 14 nM), demonstrates significant efficacy.

Mizagliflozin is an orally active, selective SGLT1 inhibitor with a Ki value of 27 nM for human SGLT1. Mizagliflozin is 303 times more selective for SGLT1 than for SGLT2. Mizagliflozin is an anti-diabetic drug that can improve postprandial blood sugar fluctuations and may have the potential to improve chronic constipation.

Pirolate is a receptor of histamine H1.

NP3-253 is an orally active NLRP3 inhibitor that can cross the blood-brain barrier. It serves as a tool for further exploring the biological properties of NLRP3 in models of peripheral and neuroinflammation.

Agerafenib (CEP32496) is a highly potent inhibitor of BRAF.

Dihydrocarminomycin is an anthracycline antibiotics.

BIBP3226 is a potent and selective antagonist for the Neuropeptide Y receptor (Y1) and the neuropeptide FF receptor (NPFF).

AT-1459 is a novel direct thrombin inhibitor with antithrombotic efficacy.

CP-320626 is a highly efficient human liver glycogen phosphorylase (GP) inhibitor with cholesterol-lowering activity. It inhibits cholesterol biosynthesis by directly inhibiting CYP51 and can be used in type 2 diabetes research.

D-erythro-Sphingosine (trans-4-Sphingenine) is a protein kinase C (PKC) inhibitor. D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator

GP3269 is a selective, potent, orally active human adenosine kinase (AK) inhibitor (IC50: 11 nM) with anticonvulsant effects in rats.

IMP-321 is a soluble dimeric recombinant form of LAG-3 and first-in-class antigen presenting cell activator.

Naboctate is a synthetic cannabinoid receptor agonist. It has antiemetic, sedative, anxiolytic and anti-glaucoma properties.

Naboctate hydrochloride is the hydrochloride form of naboctate, a synthetic cannabinoid receptor agonist. It has antiemetic, sedative, anxiolytic and anti-glaucoma properties.